AbbVie to acquire cancer drug maker Pharmacyclics in $21bn deal
US-based biopharmaceutical firm AbbVie announced Wednesday that it has agreed to acquire Pharmacyclics Inc for about $21 billion. The deal would give AbbVie control over Pharmacycl
Login
X
- New Ventures
- Market Analysis
- Emerging Markets
- Technology
- Professional Services
- Media & Entertainment
- Manufacturing & Retail
- Logistics & Supply Chain
- Healthcare & Pharmaceutical
- Financial Services
- Energy
- Autos
- Aerospace & Defense
- Work-Life Balance
- Strategic Thinking
- Productivity
- Decision Making
- Communication
- Sustainability
- Success Story
- Power Players
- Philanthropy
- People
- Innovation
- CEO Magazine
